49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-023645-29-DE
(EUCTR)
15/03/201111/01/2011Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study - FumaCLEEfficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study - FumaCLE Adult subjects of any ethnicity and either gender with Cutaneous Lupus Erythematosus lesions of Subacute Cutaneous Lupus Erythematosus (SCLE), Discoid Lupus Erythematosus (DLE), Lupus erythematosus tumidus (LET) or Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions and without major organ involvement to investigate the efficacy of fumaric acid esters in the treatment of Cutaneous Lupus Erythematosus lesions.
MedDRA version: 12.1;Level: LLT;Classification code 10056509;Term: Cutaneous lupus erythematosus
MedDRA version: 12.1;Level: PT;Term: Cutaneous lupus erythematosus
Trade Name: Fumaderm® initial
Product Name: -
Product Code: -
INN or Proposed INN: Dimethylfumarat
INN or Proposed INN: Ethylhydrogenfumarat, Calciumsalz
INN or Proposed INN: Ethylhydrogenfumarat, Magnesiumsalz
INN or Proposed INN: Ethylhydrogenfumarat, Zinksalz
Trade Name: Fumaderm®
Product Name: -
Product Code: -
INN or Proposed INN: Dimethylfumarat
INN or Proposed INN: Ethylhydrogenfumarat, Calciumsalz
INN or Proposed INN: Ethylhydrogenfumarat, Magnesiumsalz
INN or Proposed INN: Ethylhydrogenfumarat, Zinksalz
Universitätsklinikum MünsterNULLNot RecruitingFemale: yes
Male: yes
11Germany